COVID-19 boosters should start with most vulnerable: WHO

Published On 2022-01-23 03:30 GMT   |   Update On 2024-02-20 06:16 GMT

New Delhi: At a press briefing on 21 January, the UN health agency said it was now recommending booster doses of the Pfizer-BioNTech vaccine, beginning in the highest-priority groups, about four to six months after receiving the first two doses, in line with guidance from dozens of countries that embarked upon booster programs months ago.Last year, WHO pleaded with rich countries to declare...

Login or Register to read the full article

New Delhi: At a press briefing on 21 January, the UN health agency said it was now recommending booster doses of the Pfizer-BioNTech vaccine, beginning in the highest-priority groups, about four to six months after receiving the first two doses, in line with guidance from dozens of countries that embarked upon booster programs months ago.

Last year, WHO pleaded with rich countries to declare a moratorium on offering booster doses until the end of 2021, an appeal that went almost entirely ignored. The agency said its expert vaccine group assessed the increasing data about booster doses and noted the waning of immune protection over time.

Also Read:WHO recommends two new drugs to treat patients with COVID-19

Numerous studies have shown in recent months that booster doses restore antibody levels and offer strong protection against severe disease, including against COVID-19 variants like delta and omicron.

Boosters are part of the vaccination program, but it doesn't mean unfettered use to all ages, said WHO's Dr Kate O'Brien, director of immunisation, vaccines and biologicals. We continue to have the highest focus on vaccination of the highest priority groups, she said.

Also Read:COVID-19 cases Tsunami due to Omicron, Delta will drive Health Systems towards Collapse, warns WHO

Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News